This Research Topic is a call for papers to provide an up to date assessment of current attempts to introduce tolerogenic therapies into clinical practice. Tolerance has been a highly sought after goal in the field of organ transplantation for over half a century, and is now readily achievable in rodent models, but considerable barriers remain to successfully translating tolerogenic treatments to the clinic. The initial call for this Research Topic has been aimed to provide an overview of recent advances made within the European RISET and American ITN networks with regard to tolerogenic strategies in clinical transplantation, autoimmune disease, and allergy. Articles will also cover the barriers to clinical tolerance induction and new emerging approaches to overcome such barriers. 1. Collaborative networks working towards the goal of therapeutic tolerance induction 2. Prope tolerance and minimization of immunosuppression 3. Lessons from operationally tolerant patients 4. Targeted withdrawal of immunosuppression 5. Stem cells and hematopoietic chimerism as a route to tolerance 6. Promoting regulatory T cells 7. Tolerogenic dendritic cells and negative vaccination 8. Inhibitory pathways and mechanisms in tolerance 9. Memory T cells and heterologous immunity 10. The innate response to allotransplants 11. Chronic graft loss--what are the missing links? 12. The impact of graft microenvironment on tolerance

This volume presents a comprehensive overview of the latest advances in basic and translational research in the field of reconstructive transplantation and its potential therapeutic implications. Dr. Thomas E. Starzl and Dr. Raimund Margreiter, both pioneers in the field of transplantation, have written the foreword for the book. The volume spans such topics as skin rejection, immune monitoring, stem cell-based immunomodulatory strategies, costimulatory blockade, tolerance induction, chronic rejection, ischemia reperfusion injury, nerve regeneration, cortical reintegration, and small and large animal models for reconstructive transplantation. The book is intended for biomedical researchers and basic scientists in the field of reconstructive transplantation, transplant immunology and regenerative medicine, as well as clinicians, surgeons and multidisciplinary specialists, who are practicing or interested in this novel and exciting field. Postgraduate fellows and students will also find it a valuable reference.

This comprehensive, authoritative treatise covers all aspects of mucosal vaccines including their development, mechanisms of action, molecular/cellular aspects, and practical applications. The contributing authors and editors of this one-of-a-kind book are very well known in their respective fields. Mucosal Vaccines is organized in a unique format in which basic, clinical, and practical aspects of the mucosal immune system for vaccine development are described and discussed. This project is endorsed by the Society for Mucosal Immunology. - Provides the latest views on mucosal vaccines - Applies basic principles to the development of new vaccines - Links basic, clinical, and practical aspects of mucosal vaccines to different infectious diseases - Unique and user-friendly organization

Stem Cells and Biomaterials for Regenerative Medicine addresses the urgent need for a compact source of information on both the cellular and biomaterial aspects of regenerative medicine. By developing a mutual understanding between three separately functioning areas of science—medicine, the latest technology, and clinical economics—the volume encourages interdisciplinary relationships that will lead to solutions for the significant challenges faced by today's regenerative medicine. Users will find sections on the homeostatic balance created by apoptosis and proliferating tissue stem cells, the naturally regenerative capacities of various tissue types, the potential regenerative benefits of iPS-generation, various differentiation protocols, and more. Written in easily accessbile language, this volume is appropriate for any professional or medical staff looking to expand their knowledge with regard to stem cells and regenerative medicine. - Arms readers with key information on tissue engineering, artificial organs and biomaterials, while using broadly accessible language - Provides broad introduction to, and examples of, various types of stem cells, core concepts of regenerative medicine, biomaterials, nanotechnology and nanomaterials, somatic cell transdyferentiation, and more - Edited and authored by researchers with expertise in regenerative medicine, (cancer) stem cells, biomaterials, genetics and nanomaterials

Follow along as this New York Times bestselling author details the astonishing scientific discovery of the code to unleashing the human immune system to fight in this "captivating and heartbreaking" book (The Wall Street Journal). For decades, scientists have puzzled over one of medicine's most confounding mysteries: Why doesn't our immune system recognize and fight cancer the way it does other diseases, like the common cold? As it turns out, the answer to that question can be traced to a series of tricks that cancer has developed to turn off normal immune responses -- tricks that scientists have only recently discovered and learned to defeat. The result is what many are calling cancer's "penicillin moment," a revolutionary discovery in our understanding of cancer and how to beat it. In The Breakthrough, New York Times bestselling author of The Good Nurse Charles Graeber guides readers through the revolutionary scientific research bringing immunotherapy out of the realm of the miraculous and into the forefront of twenty-first-century medical science. As advances in the fields of cancer research and the human immune system continue to fuel a therapeutic arms race among biotech and pharmaceutical research centers around the world, the next step -- harnessing the wealth of new information to create modern and more effective patient therapies -- is unfolding at an unprecedented pace, rapidly redefining our relationship with this all-too-human disease. Groundbreaking, riveting, and expertly told, The Breakthrough is the story of the game-changing scientific discoveries that unleash our natural ability to recognize and defeat cancer, as told through the experiences of the patients, physicians, and cancer immunotherapy researchers who are on the front lines. This is the incredible true story of the race to find a cure, a dispatch from the life-changing world of modern oncological science, and a brave new chapter in medical history.

1. Non-viral gene therapy / Sean M. Sullivan -- 2. Adenoviral vectors / Stuart A. Nicklin and Andrew H. Baker -- 3. Retroviral vectors and integration analysis / Cynthia C. Bartholomae [und weitere] -- 4. Lentiviral vectors / Janka Matrai, Marinee K.L. Chuah and Thierry VandenDriessche -- 5. Herpes simplex virus vectors / William F. Goins [und weitere] -- 6. Adeno-Associated Viral (AAV) vectors / Nicholas Muzyczka -- 7. Regulatory RNA in gene therapy / Alfred. S. Lewin -- 8. DNA integrating vectors (Transposon, Integrase) / Lauren E. Woodard and Michele P. Calos -- 9. Homologous recombination and targeted gene modification for gene therapy / Matthew Porteus -- 10. Gene switches for pre-clinical studies in gene therapy / Caroline Le Guiner [und weitere] -- 11. Gene therapy for central nervous system disorders / Deborah Young and Patricia A. Lawlor -- 12. Gene therapy of hemoglobinopathies / Angela E. Rivers and Arun Srivastava -- 13. Gene therapy for primary immunodeficiencies / Aisha Sauer, Barbara Cassani and Alessandro Aiuti -- 14. Gene therapy for hemophilia / David Markusic, Babak Moghimi and Roland Herzog -- 15. Gene therapy for obesity and diabetes / Sergei Zolotukhin and Clive H. Wasserfall -- 16. Gene therapy for Duchenne muscular dystrophy / Takashi Okada and Shin'ichi Takeda -- 17. Cancer gene therapy / Kirsten A.K. Weigel-Van Aken -- 18. Gene therapy for autoimmune disorders / Daniel F. Gaddy, Melanie A. Ruffner and Paul D. Robbins -- 19. Gene therapy for inherited metabolic storage diseases / Cathryn Mah -- 20. Retinal diseases / Shannon E. Boye, Sanford L. Boye and William W. Hauswirth -- 21. A brief guide to gene therapy treatments for pulmonary diseases / Ashley T. Martino, Christian Mueller and Terence R. Flotte -- 22. Cardiovascular disease / Darin J. Falk, Cathryn S. Mah and Barry J. Byrne

Antibody-drug conjugates (ADCs) stand at the verge of a transformation. Scores of clinical programs have yielded only a few regulatory approvals, but a wave of technological innovation now empowers us to overcome past technical challenges. This volume focuses on the next generation of ADCs and the innovations that will enable them. The book inspires the future by integrating the field’s history with novel strategies and cutting-edge technologies. While the book primarily addresses ADCs for solid tumors, the last chapter explores the emerging interest in using ADCs to treat other diseases. The therapeutic rationale of ADCs is strong: to direct small molecules to the desired site of action (and away from normal tissues) by conjugation to antibodies or other targeting moieties. However, the combination of small and large molecules imposes deep complexity to lead optimization, pharmacokinetics, toxicology, analytics and manufacturing. The field has made significant advances in all of these areas by improving target selection, ADC design, manufacturing methods and clinical strategies. These innovations will inspire and educate scientists who are designing next-generation ADCs with the potential to transform the lives of patients.